التفاصيل البيبلوغرافية
| العنوان: |
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. |
| المؤلفون: |
Mora, Barbara, Rumi, Elisa, Guglielmelli, Paola, Barraco, Daniela, Maffioli, Margherita, Rambaldi, Alessandro, Caramella, Marianna, Komrokji, Rami, Gotlib, Jason, Kiladjian, Jean Jacques, Cervantes, Francisco, Devos, Timothy, Palandri, Francesca, Stefano, Valerio, Ruggeri, Marco, Silver, Richard T., Benevolo, Giulia, Albano, Francesco, Cavalloni, Chiara, Pietra, Daniela |
| المصدر: |
Cancer Medicine; Aug2019, Vol. 8 Issue 9, p4089-4092, 4p |
| مصطلحات موضوعية: |
MYELOFIBROSIS, SKIN cancer, THERAPEUTICS |
| مستخلص: |
Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder